ライフサイエンスコーパス: urinary tract infection

1 alidomide-dexamethasone group (pneumonia and urinary tract infection).

2 e most common adverse events were nausea and urinary tract infection.

3 ia, in the absence of signs or symptoms of a urinary tract infection.

4 are test that can guide correct treatment of urinary tract infection.

5 antibiotic prophylaxis to prevent recurrent urinary tract infection.

6 a key factor for successful establishment of urinary tract infection.

7 , the only bacterial infection of concern is urinary tract infection.

8 cellular trap generation during experimental urinary tract infection.

9 nce type 131 (ST131) in treatment failure of urinary tract infection.

10 regulating an inflammatory response during a urinary tract infection.

11 iously shown to be important in experimental urinary tract infection.

12 n mouse models of peritonitis, pneumonia and urinary tract infection.

13 modifiable factors like graft rejection and urinary tract infection.

14 high rate of bacteriuria without documented urinary tract infection.

15 s of any age without signs and symptoms of a urinary tract infection.

16 ce, including Escherichia-Shigella linked to urinary tract infections.

17 e 3 development in patients with complicated urinary tract infections.

18 l urine samples from patients diagnosed with urinary tract infections.

19 sed screening for abnormal vaginal flora and urinary tract infections.

20 step-down oral therapy to treat complicated urinary tract infections.

21 and inguinal hernias but less than that for urinary tract infections.

22 t that contains bacterial species related to urinary tract infections.

23 ed intraabdominal infections, or complicated urinary tract infections.

24 (UPEC), which cause both acute and recurrent urinary tract infections.

25 arrhoea, injection-site nodules, nausea, and urinary tract infections.

26 nd capsule-deficient mutants associated with urinary tract infections.

27 er hipA mutants cause multidrug tolerance in urinary tract infections.

28 non-spore-forming rod, are presented here as urinary tract infections.

29 sign of diseases such as hemolytic anemia or urinary tract infections.

30 1.1%-100%) of prescriptions in uncomplicated urinary tract infections.

31 (54%) were reported from catheter-associated urinary tract infections.

32 n vitro biofilm formation and persistence in urinary tract infections.

33 nic matrix that are strictly associated with urinary tract infections.

34 ly prescribed drug in the treatment of acute urinary tract infections.

35 Escherichia coli (UPEC), the major cause of urinary tract infections.

36 al agents, for instance, in the treatment of urinary tract infections.

37 tsS/BtsR importance during acute and chronic urinary-tract infections.

38 ons were 14 versus 7 for catheter-associated urinary tract infection, 13 versus 8 for ventilator-asso

39 ryngitis (38 [14%] vs 36 [12%] vs 39 [15%]), urinary tract infection (19 [7%] vs 11 [4%] vs 13 [5%]),

40 a (4.5%), nonspecific chest pain (3.7%), and urinary tract infection (3.2%).

41 ratory tract infection (3 [7%] vs none], and urinary tract infections (3 [7%] vs 1 [2%]).

42 ear, nose, and throat infections (55 [7%]), urinary tract infections (37 [5%]), and surgical-site in

43 (58.98% vs 14.81%; OR, 8.53; CI, 7.41-9.83), urinary tract infection (38.41% vs 8.60%; OR, 7.81; CI,

44 ade >/=3 infections included pneumonia (8%), urinary tract infection (4%), and cellulitis (3%).

45 95% CI: 0.97-2.84; I2: 86%; p-value = 0.06), urinary tract infection (4,493 FGM/C and 3,776 non-FGM/C

46 was consistent across infection subtypes of urinary tract infection (482 cases), cellulitis/osteomye

47 h bempedoic acid and placebo, respectively), urinary tract infection (5.0% vs 1.9%), and hyperuricemi

48 00 for community-acquired pneumonia, 112 for urinary tract infection, 83 for intra-abdominal infectio

49 elop a point-of-care susceptibility test for urinary tract infection, a disease that 100 million wome

50 events [6.1%]; placebo, 105 events [5.8%]), urinary tract infection (aclidinium, 93 events [5.2%]; p

51 ower rates of ileus, Foley re-insertion, and urinary tract infection (all P < 0.01).

52 quired bloodstream infection, pneumonia, and urinary tract infection; all-cause ICU mortality; and le

53 dentification of microbial pathogens causing urinary tract infections allow prompt and specific treat

54 best available therapy (137 with complicated urinary tract infection and 11 with complicated intra-ab

55 li (ExPEC) is the leading cause in humans of urinary tract infection and bacteremia.

56 this question in a mouse model of recurrent urinary tract infection and found that a prior bladder i

57 diabetes, and graft function, posttransplant urinary tract infection and rejection treatment were imp

58 Urinary tract infection and rejection treatment were not

59 ger percent burn and with the development of urinary tract infection and sepsis postadmission, regard

60 ceftazidime-avibactam (144 with complicated urinary tract infection and ten with complicated intra-a

61 History A 52-year-old man with a history of urinary tract infections and a previous clinical diagnos

62 to identify potential mechanisms leading to urinary tract infections and associated morbidities in b

63 Escherichia coli associated with urinary tract infections and bacteremia has been intensi

64 range of diseases, including respiratory and urinary tract infections and bacteremia.

65 ts when used in the treatment of complicated urinary tract infections and complicated intra-abdominal

66 23 individuals diagnosed with polymicrobial urinary tract infections and found that most interaction

67 well described for ExPEC strains that cause urinary tract infections and meningitis, they have not b

68 In addition, it resulted in a higher risk of urinary tract infections and need for transient self-cat

69 nistration for the management of complicated urinary tract infections and pyelonephritis caused by su

70 ome may be used to predict susceptibility to urinary tract infections and sepsis in burn patients.

71 extraintestinal sites to cause diseases like urinary tract infections and sepsis.

72 ates of RTI, skin and soft-tissue infection, urinary tract infection, and bloodstream infection varie

73 h as kidney disorder, urinary stone disease, urinary tract infection, and cystic fibrosis.

74 gnoses as upper respiratory tract infection, urinary tract infection, and influenza-like illness occu

75 etiologies for fever, prematurely diagnosing urinary tract infection, and prescribing unnecessary ant

76 bserved 2 UC (ureteric leak and stenosis), 8 urinary tract infections, and 9 stent-related symptoms.

77 e diseases like sepsis, acute kidney injury, urinary tract infections, and HIV/AIDS.

78 a range of infections, including pneumonias, urinary tract infections, and septicemia, in otherwise h

79 ons-including 32 with bacteremia and 15 with urinary tract infections-and 190 without bacterial infec

80 Lower urinary tract infections are among the most common human

81 Urinary tract infections are commonly caused by alpha-he

82 Severe urinary tract infections are commonly caused by sub-stra

83 Urinary tract infections are considered among the most c

84 Urinary tract infections are one of the most common reas

85 treatment of complicated intra-abdominal and urinary tract infections, as well as hospital-acquired p

86 ant pathogens responsible for intestinal and urinary tract infections, as well as sepsis and hemolyti

87 ing methodology, among patients suspected of urinary tract infection at 11 sites in Indonesia.

88 ic reflux in children who have had a febrile urinary tract infection be reduced, but this approach is

89 ovel findings include clinically significant urinary tract infections by Actinomyces neuii (21%) and

90 fumarate for 8 months presented with fever, urinary tract infection caused by Escherichia coli, anal

91 ted intraabdominal infection, or complicated urinary tract infection caused by imipenem-nonsusceptibl

92 Urinary tract infections caused by the bacterium Escheri

93 Urinary tract infections caused by uropathogenic Escheri

94 Urinary tract infections caused by uropathogenic Escheri

95 hat most commonly define catheter-associated urinary tract infection (CAUTI) and encourage further ex

96 Catheter-associated urinary tract infection (CAUTI) is the commonest hospita

97 Catheter associated urinary tract infection (CAUTI) is the most common healt

98 p the first A. baumannii catheter-associated urinary tract infection (CAUTI) murine model using UPAB1

99 is an emerging cause of catheter-associated urinary tract infection (CAUTI), which frequently progre

100 welling catheter use and catheter-associated urinary tract infection (CAUTI).

101 tals struggle to prevent catheter-associated urinary tract infection (CAUTI).

102 en and frequent cause of catheter-associated urinary tract infection (CAUTI).

103 personnel and number of catheter-associated urinary tract infections (CAUTI) and central line-associ

104 e focused on the risk of catheter-associated urinary tract infections (CAUTI) caused by Escherichia c

105 ulting in false positive catheter-associated urinary tract infections (CAUTI).

106 Catheter-associated urinary tract infections (CAUTIs) are common hospital-ac

107 n detecting the onset of catheter-associated urinary tract infections (CAUTIs) is also demonstrated b

108 am infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), ventilator-associated

109 During Escherichia coli urinary tract infections, cells in the human urinary tra

110 italization with major infection (pneumonia, urinary tract infection, cellulitis and osteomyelitis, a

111 italization with major infection (pneumonia, urinary tract infection, cellulitis and osteomyelitis, a

112 enic E. coli (UPEC) is the dominant cause of urinary tract infections, clinically described as cystit

113 erences in rates of postoperative pneumonia, urinary tract infection, Clostridium difficile colitis,

114 coli (UPEC), the primary causative agents of urinary tract infections, colonize and invade the epithe

115 being developed for treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis

116 m and doripenem in patients with complicated urinary tract infection (cUTI), including acute pyelonep

117 Complicated urinary tract infections (cUTIs) are responsible for a m

118 The most common infections were urinary tract infection (cystitis) (34.9% vs 25.2%), cyt

119 Episodes of urinary tract infection (cystitis) occurred more often i

120 for most spending related to admissions for urinary tract infections, dehydration, heart failure, an

121 Our data reveal potential links for urinary tract infection development and several morbidit

122 wardship in the era of increasing numbers of urinary tract infections due to extensively drug-resista

123 rence to study medication, or development of urinary tract infection during the study.

124 Vesicoureteral Reflux trial and the Careful Urinary Tract Infection Evaluation Study).

125 erichia coli, the primary causative agent of urinary tract infections, expresses type 1 and P pili re

126 ed 32 ventilator-associated pneumonia, eight urinary tract infections, five blood stream infections,

127 ent) and precipitating factors (for example, urinary tract infection) for delirium have been describe

128 of abdominal pain, bloating, diarrhoea, and urinary tract infection [grade 3]; aneurysm [grade 4]),

129 The widespread occurrence of urinary tract infections has resulted in frequent antibi

130 Frequent antibiotic treatment of urinary tract infections has resulted in the emergence o

131 In human urinary tract infections, host cells release the antimic

132 4 adverse events in the letrozole group were urinary tract infection, hypokalaemia, and left ventricu

133 ally tested positive), and 71% in those with urinary tract infections (ie, resolution in 224 [71%] of

134 reteric stenosis in 31 (44%) of 71 patients, urinary tract infection in 23 (32%), haematuria in 22 (3

135 events reported as related to treatment were urinary tract infection in one (1%) participant in the t

136 cherichia coli, the major causative agent of urinary tract infections in humans.

137 h of nine antibiotics that are used to treat urinary tract infections in minutes.

138 2 patients and in ten [28%] of 36 patients), urinary tract infections (in one [8%] of 12 and in six [

139 istration (FDA) for treatment of complicated urinary tract infections, including pyelonephritis, in a

140 Increased rates of Escherichia coli urinary tract infections, increasing resistance to ampic

141 a single site of infection (eg, complicated urinary tract infections, intra-abdominal infections), y

142 Antibiotic prescribing for a presumed urinary tract infection is often preceded by inappropria

143 strategy for patients suspected of having a urinary tract infection is to test for pyuria and bacter

144 The incidence rate for catheter-associated urinary tract infections is between 3% and 7% for each d

145 Treatment of complicated urinary-tract infections is challenging due to rising an

146 Escherichia coli (UPEC), a leading cause of urinary tract infections, is associated with prostate an

147 t Escherichia coli and Enterococcus faecalis urinary tract infection isolates.

148 During experimental urinary tract infection, MAITs migrated to the bladder a

149 infection, ventilator-associated pneumonia, urinary tract infection, mean ventilator-free days, mean

150 Moreover, in a murine urinary tract infection model, CFT073 infection rapidly

151 formation as well as attenuation in a murine urinary tract infection model.

152 oding a virulence factor in endocarditis and urinary tract infection models, has been shown to increa

153 (n=10 [12%]), peripheral oedema (n=9 [11%]), urinary tract infections (n=9 [11%]), and orthostatic hy

154 ommon agent of sepsis and community-acquired urinary tract infections, obtained during the course of

155 ory Activities, version 21.0), most commonly urinary tract infections, occurred more frequently with

156 s with antibiotic-resistant Escherichia coli urinary tract infections (odds ratio [OR] = 4.19; 95% co

157 Escherichia coli is the leading cause of urinary tract infection, one of the most common bacteria

158 IIB092 2100 mg: two severe adverse events of urinary tract infection, one severe adverse event of cha

159 ailable therapy in patients with complicated urinary tract infection or complicated intra-abdominal i

160 ients were aged 18-90 years with complicated urinary tract infection or complicated intra-abdominal i

161 would not increase the risk of developing a urinary tract infection or increase the burden of use to

162 yuria and a diagnosis of a complicated lower-urinary-tract infection or pyelonephritis were randomly

163 treatment of patients with complicated lower-urinary-tract infections or pyelonephritis.

164 ofloxacin in patients with complicated lower-urinary-tract infections or pyelonephritis.

165 ions (OR = 7.0; CI, 1.7-28.3; P = .006), and urinary tract infection (OR = 0.04; CI, 0.3-0.9; P = .02

166 ty (OR, 5.24; 95% CI, 2.15-12.77), recurrent urinary tract infections (OR, 0.97; 95% CI, 0.27-3.45),

167 sculoskeletal low back pain (nepholithiasis, urinary tract infection, osteomyelitis, cholecystitis, o

168 n quality indicators and catheter-associated urinary tract infection outcomes in intensive care units

169 hospital discharge with a diagnosis code for urinary tract infection, pneumonia, cellulitis/osteomyel

170 ection (SSI), deep/organ-space SSI, any SSI, urinary tract infection, pneumonia, sepsis, deep venous

171 Urinary tract infection-positive burn patients with alte

172 comprised rejection, acute tubular necrosis, urinary tract infection/pyelonephritis, viral nephritis,

173 Recurrent urinary tract infections (R-UTIs) are the main cause of

174 Recurrent urinary tract infections (R-UTIs) are the main cause of

175 nd no difference in complications, including urinary tract infection rates, between those using singl

176 staff, without detrimental impact on UC and urinary tract infection rates.

177 ve complications from BPH, such as recurrent urinary tract infections, refractory urinary retention,

178 rimegepant n=11 [2%]; placebo n=3 [<1%]) and urinary tract infection (rimegepant n=10 [1%]; placebo n

179 Recurrent urinary tract infection (rUTI) is a major medical proble

180 Recurrent urinary tract infections (rUTIs) are extremely common, w

181 Women suffering from recurrent urinary tract infections (rUTIs) are routinely treated f

182 sociates with an increased risk of recurrent urinary tract infections (rUTIs) linked to uropathogenic

183 c obstructive pulmonary disease, arrhythmia, urinary tract infection, septicemia, and stroke from 200

184 12), headache (five and three vs eight), and urinary-tract infections (six and two vs two).

185 Urinary tract infections still remain a concern in febri

186 dependence, progressive renal insufficiency, urinary tract infection, stroke, venous thromboembolism,

187 her an E. faecalis or Pseudomonas aeruginosa urinary tract infection, suggesting a role for urinary a

188 l role in the innate immune response against urinary tract infections, the structural basis and mecha

189 niae causes a wide range of infections, from urinary tract infections to pneumonia.

190 nia, bacterial meningitis, yeast infections, urinary tract infections, tonsillectomy, childhood ear i

191 group), pneumonia (training: 2, control: 0), urinary tract infection (training: 2, control: 0), dehyd

192 s: pneumonia, surgical site infection (SSI), urinary tract infection, transfusion/bleed events, and a

193 pyrexia (three [4%]), diarrhoea (two [3%]), urinary tract infection (two [3%]), and acute kidney inj

194 richia coli (UPEC), the predominant cause of urinary tract infections, undergoes a transient intracel

195 e, which had been standard treatment against urinary tract infections until widespread resistance dec

196 use only, particularly for outcomes such as urinary tract infection, urethral injury and quality of

197 e patients and in samples from patients with urinary tract infection using real-time reverse transcri

198 ravelers' diarrhea (TD) (75/90 subjects) and urinary tract infection (UTI) (3/90).

199 0) is a leading cause of multidrug-resistant urinary tract infection (UTI) and bloodstream infection

200 spitalized patients treated for pneumonia or urinary tract infection (UTI) and determine whether over

201 tected escherichelin during clinical E. coli urinary tract infection (UTI) and experimental human col

202 be used to monitor the onset or prognosis of urinary tract infection (UTI) and some sexually-transmit

203 signaling networks controlled by CD14 during urinary tract infection (UTI) are unknown.

204 ed a household in which 2 young children had urinary tract infection (UTI) caused by an extended-spec

205 ts presented to the ED with an ICD 9/10 code urinary tract infection (UTI) diagnosis during July 2015

206 e 216Dx in comparison to UA for diagnosis of urinary tract infection (UTI) in children.

207 ive/adjunct screening tool to UA to rule out urinary tract infection (UTI) in children.

208 clinically relevant bacteria known to cause urinary tract infection (UTI) in millions of patients.

209 ing or withholding antibiotics for suspected urinary tract infection (UTI) in older patients.

210 Catheter-associated urinary tract infection (UTI) is a common device-associa

211 Urinary tract infection (UTI) is a major global infectio

212 gnosis of asymptomatic bacteriuria (ASB) and urinary tract infection (UTI) is based on the presence o

213 nnecessary antibiotic treatment of suspected urinary tract infection (UTI) is common in long-term car

214 Urinary tract infection (UTI) is one of the most common

215 A significant proportion of urinary tract infection (UTI) patients experience recurr

216 The contribution of genetic variation to urinary tract infection (UTI) risk in children with vesi

217 Women with uncomplicated urinary tract infection (UTI) symptoms are commonly trea

218 lthy adult women with a history of recurrent urinary tract infection (UTI) to receive a single inject

219 For urinary tract infection (UTI), a history of two or more

220 Secondary outcomes were symptomatic urinary tract infection (UTI), all-cause death, all-caus

221 National guidelines for pneumonia (PNA), urinary tract infection (UTI), and acute bacterial skin

222 r respiratory tract infection (RTI), skin or urinary tract infection (UTI), and antibiotic prescripti

223 ys, including surgical site infection (SSI), urinary tract infection (UTI), and lower respiratory tra

224 ysed urinary microbial ATP as a biomarker of urinary tract infection (UTI), confirming the capability

225 et for uropathogenic E. coli (UPEC)-mediated urinary tract infection (UTI), its contribution to UPEC

226 To investigate RNase 7's role in preventing urinary tract infection (UTI), we quantified urinary RNa

227 ment of underlying ARD, and risk factors for urinary tract infection (UTI), were recorded.

228 One such area is urinary tract infection (UTI), which is one of the most

229 sion in the kidney, we addressed its role in urinary tract infection (UTI), which remains largely unk

230 iption of uropathogens in women experiencing urinary tract infection (UTI)-like symptoms.

231 nd regulation of inflammation in response to urinary tract infection (UTI).

232 ta and future development of bacteriuria and urinary tract infection (UTI).

233 ory infection, intra-abdominal infection, or urinary tract infection (UTI).

234 Streptococcus agalactiae can cause urinary tract infection (UTI).

235 in vitro and disease severity in a model of urinary tract infection (UTI).

236 septic condition but has not been studied in urinary tract infection (UTI).

237 by Escherichia coli strains associated with urinary tract infection (UTI).

238 gold standard diagnostic test for confirming urinary tract infection (UTI).

239 The most common infections were urinary tract infection (UTI; 46.8%) and pneumonia (28.2

240 Urinary tract infections (UTI) are one of the most commo

241 Diagnosing urinary tract infections (UTI) in nursing home residents

242 oli (UPEC) is the major cause of 150 million Urinary Tract Infections (UTI) reported annually world-w

243 richia coli (UPEC) accounts for 80 to 90% of urinary tract infections (UTI), and the increasing rate

244 s the major causative agent of uncomplicated urinary tract infections (UTI).

245 ng Escherichia coli ( E. coli) isolated from urinary-tract infection (UTI) samples.

246 Urinary tract infection (UTIs) was higher in CC group (4

247 uropathogenic E. coli - the primary cause of urinary tract infections (UTIs) - can adhere to vaginal

248 ned susceptibility of clinical isolates from urinary tract infections (UTIs) after 15 min of exposure

249 Disorders such as recurrent urinary tract infections (UTIs) and interstitial cystiti

250 Urinary tract infections (UTIs) and sexually transmitted

251 richia coli strains from 10 men with febrile urinary tract infections (UTIs) and their female sex par

252 Urinary tract infections (UTIs) are a common occurrence

253 Urinary tract infections (UTIs) are a major burden to hu

254 Urinary tract infections (UTIs) are a microbial disease

255 Urinary tract infections (UTIs) are among the most commo

256 Urinary tract infections (UTIs) are among the most commo

257 Urinary tract infections (UTIs) are among the most commo

258 Urinary tract infections (UTIs) are common and in genera

259 Urinary tract infections (UTIs) are common health-care-a

260 Urinary tract infections (UTIs) are common in both inpat

261 Urinary tract infections (UTIs) are common, recurrent in

262 Urinary tract infections (UTIs) are frequent and lead to

263 Complicated urinary tract infections (UTIs) are frequent in immunosu

264 Urinary tract infections (UTIs) are frequently encounter

265 Urinary tract infections (UTIs) are one of the most comm

266 Urinary tract infections (UTIs) are potentially life thr

267 Urinary tract infections (UTIs) are the most commonly re

268 Urinary tract infections (UTIs) caused by Escherichia co

269 Urinary tract infections (UTIs) caused by uropathogenic

270 ntibiotics for recurrent multidrug-resistant urinary tract infections (UTIs) disrupt the gut microbio

271 Urinary tract infections (UTIs) in children are among th

272 The treatment of urinary tract infections (UTIs) in kidney transplant rec

273 Urinary tract infections (UTIs) occur commonly, but rece

274 Urinary tract infections (UTIs) occur predominantly in f

275 Urinary tract infections (UTIs) represent a major burden

276 Urinary tract infections (UTIs) typically evoke prompt a

277 Prior studies evaluating risk for severe urinary tract infections (UTIs) with sodium-glucose cotr

278 ble hematuria, migration, fragmentation, and urinary tract infections (UTIs) within 3 mo of transplan

279 of hospital-associated infections, including urinary tract infections (UTIs), bacteremia, and infecti

280 domly assigned 609 patients with complicated urinary tract infections (UTIs), including acute pyelone

281 ExPEC causes the vast majority of urinary tract infections (UTIs), is a leading cause of a

282 It is associated with urinary tract infections (UTIs), one of the most common

283 he acute pyelonephritis that can result from urinary tract infections (UTIs), which commonly ascend f

284 nd long durations of therapy for symptomatic urinary tract infections (UTIs), yet large-scale evaluat

285 cherichia coli (UPEC) a fitness advantage in urinary tract infections (UTIs).

286 (UPEC) is the primary cause of uncomplicated urinary tract infections (UTIs).

287 nths) and prevalence of antibiotic-resistant urinary tract infections (UTIs).

288 (UPEC) bacteria are a causative pathogen of urinary tract infections (UTIs).

289 a significant number of catheter-associated urinary tract infections (UTIs).

290 s the major causative agent of uncomplicated urinary tract infections (UTIs).

291 The aRRs were increased particularly for urinary tract infections (UTIs, 1.41; 95% CI, 1.35 to 1.

292 caution), that less severe outcomes (such as urinary tract infections [UTIs] managed in the community

293 The effect of complications, such as urinary tract infection, venous thromboembolism, and myo

294 s a composite outcome of catheter-associated urinary tract infection, ventilator-associated pneumonia

295 oodstream infection, and catheter-associated urinary tract infection was 14.7 per 1000 ventilator-day

296 ora was 16.3% (95% CI 15.1-17.6) and that of urinary tract infection was 8.6% (7.7-9.5).

297 bles, being married or having a history of a urinary tract infection was associated with lower urinar

298 Urinary tract infections were more frequent in the onabo

299 as associated with more frequent episodes of urinary tract infections, whereas other infections occur

300 ndamycin (300 mg twice daily for 5 days) and urinary tract infections with cefixime (400 mg once dail